.
MergerLinks Header Logo

New Deal


Announced

SuperBac Biotechnology Solutions to go public via merger with XPAC Acquisition in a $500m deal.

Financials

Edit Data
Transaction Value£389m
Consideration TypeCash
Capital Owned-
Capital Bid For100%
EV/Sales-
EV/EBITDA-
Share Price Premium-
One Off Charge-

Tags

Edit

De-SPAC

Single Bidder

Pending

Private

biotechnology company

Brazil

Acquisition

Biotechnology

Friendly

Cross Border

Reverse Takeover

Majority

Synopsis

Edit

SuperBac Biotechnology Solutions, a biotech company in Brazil, agreed to go public via merger with XPAC Acquisition, a publicly-traded special purpose acquisition company, in a $500m deal. "We believe that our target segments within the biotechnology market have significant potential to expand in the coming years, and that with this business combination, SuperBac is very well positioned to capitalize on growth opportunities. We understand that innovation and technology play a strategic role in driving sustainable growth and redefining the future of biotechnology, and SuperBac is at the forefront of this movement," Luiz Chacon, SuperBac Founder and CEO.

© COPYRIGHT 2024 MERGERLINKS LIMITED.

ALL RIGHTS RESERVED.

15 BONHILL STREET, LONDON, EC2A 4DN, UNITED KINGDOM.

CONTACT US